Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice
Open Access
- 14 March 2006
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 58
Abstract
Background: In human breast cancers, amplification of chromosome 11q13 correlates with lymph node metastasis and increased mortality. To date, two genes located within this amplicon, CCND1 and EMS1, were considered to act as oncogenes, because overexpression of both proteins, respectively cyclin D1 and cortactin, correlated well with 11q13 amplification. Cyclin D1 is involved in cell cycle regulation and the F-actin-binding protein cortactin in cytoskeletal dynamics and cell migration. To study the role of cortactin in mammary gland tumorigenesis, we examined mouse mammary tumor virus (MMTV)-cortactin transgenic mice and MMTV-cortactin/-MMTV-cyclin D1 bitransgenic mice. Methods: MMTV-cortactin transgenic mice were generated and intercrossed with previously described MMTV-cyclin D1 transgenic mice. Immunohistochemical, Northern and Western blot analyses were performed to study the expression of human transgene cortactin during mammary gland development and in mammary tumors. For tumor incidence studies, forced-bred, multiparous mice were used to enhance transgene expression in the mammary gland. Microscopical examination was performed using haematoxylin and eosin staining. Results: Mammary gland tumors arose stochastically (incidence 21%) with a mean age of onset at 100 weeks. This incidence, however, did not exceed that of aged-matched control FVB/N mice (38%), which unexpectedly, also developed spontaneous mammary gland tumors. We mimicked 11q13 amplification by generating MMTV-cortactin/-MMTV-cyclin D1 bitransgenic mice but did not observe any synergistic effect of cortactin on cyclin D1-induced mammary hyperplasias or carcinomas, nor development of distant metastasis. Conclusion: From this study, we conclude that development of (pre-malignant) breast tumors in either wild type or MMTV-cyclin D1 mice was not augmented due to mammary gland targeted overexpression of human cortactin.Keywords
This publication has 45 references indexed in Scilit:
- Trends in incidence of and mortality from cancer in The Netherlands in the period 1989–1998European Journal of Cancer, 2003
- EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalOncogene, 1998
- Cancer Cell CyclesScience, 1996
- Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell linesInternational Journal of Cancer, 1996
- Cyclin D1/PRAD1 as a central target in oncogenesisJournal of Laboratory and Clinical Medicine, 1996
- Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines.1996
- The cyclin D1/PRAD1 oncogene in human neoplasia.1995
- Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer.1992
- Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.1992
- D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1.1991